Newborns in the neonatal intensive care unit (NICU), especially premature ones with immature organ systems, frequently suffer nosocomial infections caused by microorganisms resistant to narrow-spectrum antibiotics like ampicillin and gentamicin and require introduction of new agents with a wider spectrum of activity. Meropenem has activity against wide variety of Gram-negative and Gram-positive bacteria. It is well tolerated by children and neonates, including preterm babies, and allowing monotherapy instead of combined therapy. Severe neonatal infections with increasing antibiotic resistance are major problems affecting morbidity and mortality in the NICU. Few number of new antibacterial agents entering the clinic and new agents for multi-drug resistant Gram-negative bacteria will unlikely be available in the near future.
More research into existing antibiotics with novel mechanisms of action are required to combat the increased resistance and decreased development of antibiotics. Efforts were exerted to maximize antibiotic efficacy by optimal dosing based on pharmacodynamic and pharmacokinetic properties of antibiotics. Meropenem is administered mostly via a 30-min infusion, as some data indicate rapid degradation after reconstitution. Dose recommendations from two pediatric studies using Monte Carlo simulation have emphasized that a 4-h infusion may be needed if microorganisms showed increased minimal inhibitory concentrations (MICs), more specifically, for Pseudomonas aeruginosa. A prolonged-infusion strategy has not been tested in neonates, although some data suggest that extremely small infusion volumes may significantly affect the drug amount actually delivered. Aim of work: The objective of our study is to compare the clinical and bacteriological efficacy of conventional intermittent dosing of meropenem to the prolonged infusions in critically-ill neonates, with a proactive focus on reducing ventilator days in ventilated patients, length of stay in NICU, and neonatal mortality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
Clinical outcome
* Success is defined as complete or partial resolution of leukocytosis, temperature, and clinical signs and symptoms of infection. * Failure consists of persistence or progression of signs and symptoms of infection, development of new clinical findings consistent with active infection, or death from infection.
Time frame: 15-28 days from Meropenem treatment
Microbiological outcome
* Success is defined as eradication of infection or colonization which means detection of a new pathogen from the site of infection during meropenem therapy and no new antibiotic is indicated * Failure is defined as persistence of infection and superinfection which means detection of a new pathogen from the site of infection during meropenem therapy and new antibiotic is indicated.
Time frame: 7-21 days from Meropenem treatment
Meropenem-related length of mechanical ventilation
The number of mechanical ventilation days from the start of meropenem administration
Time frame: 0-31 days from Meropenem treatment
Meropenem-related length of NICU stay
The number of days from the beginning of meropenem therapy to discharge from NICU
Time frame: 10 weeks from Meropenem treatment
NICU mortality
Death before discharge
Time frame: 12 weeks from time of admission
Duration of meropenem treatment
Total days of meropenem treatment
Time frame: 3-28 days
Clinical side effects of meropenem treatment
Safety of meropenem therapy will be evaluated by clinical symptoms (diarrhea, rash, vomiting and seizures).
Time frame: 3-28 days from meropenem treatment
Laboratory derangement related to meropenem treatment
Assessment of laboratory parameters and their changes during meropenem therapy (transaminases, alkaline phosphatase, bilirubin).
Time frame: 3-28 days from meropenem treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.